A Phase 1/2 Dose Escalation and Expansion Study of Combination APL-501 or Nivolumab With APL-101 in Locally Advanced or Metastatic Hepatocellular and Renal Cell Carcinoma
Phase of Trial: Phase I/II
Latest Information Update: 07 Jun 2019
Price : $35 *
At a glance
- Drugs Bozitinib (Primary) ; Genolimzumab (Primary) ; Nivolumab (Primary)
- Indications Carcinoma; Liver cancer; Renal cell carcinoma
- Focus Adverse reactions
- Acronyms APOLLO-1
- Sponsors Apollomics
- 18 Sep 2018 According to CBT Pharmaceuticals media release, the first patient has been dosed in this study and initiated the APOLLO program.
- 10 Sep 2018 Status changed from not yet recruiting to recruiting.
- 30 Aug 2018 Status changed from not stated to not yet recruiting.